Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.38% | 1.37% | 1.92% | 0.65% | -0.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.38% | 1.37% | 1.92% | 0.65% | -0.88% |
| Cost of Revenue | 2.57% | 4.62% | 6.82% | 6.09% | 2.82% |
| Gross Profit | 0.31% | -1.47% | -2.25% | -3.93% | -3.97% |
| SG&A Expenses | 3.84% | 3.07% | 4.07% | 3.39% | 1.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.25% | 1.58% | 3.03% | 3.31% | 2.22% |
| Operating Income | 2.58% | -0.59% | -7.77% | -20.26% | -23.32% |
| Income Before Tax | 256.68% | -22.15% | 108.08% | 142.50% | 16.18% |
| Income Tax Expenses | 278.34% | -2.22% | 109.13% | 147.28% | 26.41% |
| Earnings from Continuing Operations | 251.34% | -30.33% | 107.80% | 141.20% | 13.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 251.34% | -30.33% | 107.80% | 141.20% | 13.20% |
| EBIT | 2.58% | -0.59% | -7.77% | -20.26% | -23.32% |
| EBITDA | 2.44% | 2.66% | -1.14% | -10.16% | -13.08% |
| EPS Basic | 256.97% | -29.25% | 108.02% | 143.01% | 10.93% |
| Normalized Basic EPS | 6.17% | 6.23% | -4.90% | -10.69% | -18.48% |
| EPS Diluted | 256.19% | -29.72% | 107.96% | 142.91% | 11.09% |
| Normalized Diluted EPS | 5.89% | 6.16% | -4.90% | -10.70% | -18.43% |
| Average Basic Shares Outstanding | -2.39% | -3.16% | -3.74% | -3.36% | -3.14% |
| Average Diluted Shares Outstanding | -2.16% | -3.11% | -3.75% | -3.36% | -3.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |